Member Info for zebbo

Be interesting to see where the Hardy's stand. That could be pivotal

Looking at the share register there is very little chance of this being voted down without institutional support. Only other chance is to flush out a potential bidder

They will be looking for full control and sell on, as we have given away our valuable paper . Mercuria know that, cracking deal for them

Why buy UK assets, just so you can pay 75% tax. Better idea would be to buy elsewhere and run down the UK assets.
It should not be a hard decision with these sort of punitive taxes, coupled with unstable political landscape

IMO SQZ, should buy back 50% and then offer £1 divi. That would get the SP moving North by the tune of ~£2

The BOD need to held to account here for lack of value creation. Especially after the duster.

Whos company is it....

I expect as we move to equilibrium (Mcap=Cash) It becomes a no brainer for PE or other suitor. They could just milk the assets no need to think about growth, shareholders etc. Sit back and coin it in.
No hedging required with the price of gas fcast to be high for the next 2 years at least

MaryBR - Agree I went from £50k down to £10k up, sold the lot at 15.61. Let it settle then take another look

OPTI has been over hyped by some low grade share pundits/journalists. The realization after the many deals is that OPTI will never make a profit. The ingredients on offer appear good, however they are not mainstream and volume is pitiful Vs the amount of deals struck. This will not change, many years of trying tells you that surely. Flogging a dead horse is a saying that springs to mind

thats 82500 pints for me

GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.

hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis?

new advisor, usually means an equity raise is on its way

where have they all gone??. As usual the BS keyboard warriors have melted away

You watch sentiment change along with the SP as the first few deals get signed

I have also bought a few today for the long term / divi

AAS - Mate you need to keep up. Lawsuits are all part and parcel of the industry. History tells you that clearly

Third quarter 2022 results on Wednesday 2 November.

Are we prepared to zero this, because this is where we are heading. So much early promise followed by years of ramping. OPTI is like to fall on its sword at some point. The numbers remain weak

just a load of "he" said "she" said

.....at group whose research helped spark a wave of lawsuits, interesting

hTTps://archive.md/GtBmU

I'll tell you where the SP is going £17 in 12 months. Step back take an objective view of what is happening in the world. Then ask yourself if GSK is a save place to invest